Cerevel Therapeutics Holdings, Inc. (CERE) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist Ronald C. Renaud Jr.,.
CERE hat IPO-Datum 2020-07-30, 355 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $8.19B.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases including schizophrenia, epilepsy, Parkinson's disease, and psychiatric disorders. The company's pipeline includes several lead programs in clinical development, such as emraclidine for schizophrenia, Darigabat for drug-resistant epilepsy and anxiety, and Tavapadon for Parkinson's disease, alongside multiple earlier-stage candidates targeting conditions like dementia-related apathy, substance use disorder, and major depressive disorder. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel leverages multiple molecular mechanisms and receptor targets to address critical unmet needs in central nervous system disorders.
